| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787875 | Journal of Thoracic Oncology | 2018 | 37 Pages |
Abstract
These data suggest that 60% of patients with MPM characterized by either PD-L1 expression or an inflamed status are attractive candidates for cancer immunotherapeutic options.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Namrata S. PhD, Luisella MD, PhD, Hartmut MD, PhD, Wei PhD, Stefania MLT, Federica MD, Roberta BSc, Marco PhD, Valentina PhD, Consuelo MD, Silvia MD, PhD, Priti S. PhD, Mauro MD, Marcin PhD, Giorgio V. MD,